Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 25, 2022 16:05 ET | Source: Otonomy, Inc.

Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Top-line results for OTO-313 Phase 2 trial in tinnitus expected in August 2022; patient enrollment completed for clinical safety evaluation of higher and bilateral dosing of OTO-313 with top-line...
May 09, 2022 16:04 ET | Source: Otonomy, Inc.

Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update

Positive top-line results announced for OTO-413 Phase 2a in hearing loss; enrollment ongoing for higher dose evaluationOTO-313 Phase 2 trial in tinnitus fully enrolled with top-line results expected...
May 02, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update

SAN DIEGO, May 02, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will...
March 15, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Host Virtual Investor R&D Event on March 22, 2022

SAN DIEGO, March 15, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
February 28, 2022 16:27 ET | Source: Otonomy, Inc.

Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

OTO-313 Phase 2 trial in tinnitus fully enrolled ahead of schedule with top-line results expected in mid-2022; initiating safety evaluation of higher and bilateral dosingOTO-413 Phase 2a cohort in...
February 28, 2022 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
November 16, 2021 07:30 ET | Source: Otonomy, Inc.

Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its...
January 26, 2016 07:05 ET | Source: Otonomy, Inc.

Otonomy Announces Publication Supporting Development of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss

SAN DIEGO, Jan. 26, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
January 12, 2016 09:27 ET | Source: Otonomy, Inc.

Otonomy Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO, Jan. 12, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
January 08, 2016 07:00 ET | Source: Otonomy, Inc.

Otonomy to Present at J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 08, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...

Next Page keyboard_arrow_right